Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
K Wang, YJ Xiang, HM Yu, YQ Cheng, ZH Liu, YY Qin… - Nature Medicine, 2024 - nature.com
Hepatocellular carcinoma (HCC), particularly when accompanied by microvascular invasion
(MVI), has a markedly high risk of recurrence after liver resection. Adjuvant immunotherapy …
(MVI), has a markedly high risk of recurrence after liver resection. Adjuvant immunotherapy …
Increased co-expression of PD1 and TIM3 is associated with poor prognosis and immune microenvironment heterogeneity in gallbladder cancer
X He, Y Peng, G He, H Ye, L Liu, Q Zhou, J Shi… - Journal of Translational …, 2023 - Springer
Background The effectiveness of immune checkpoint inhibitors in treating gallbladder
cancer (GBC) remains unsatisfactory. Recently, several new immune checkpoints have …
cancer (GBC) remains unsatisfactory. Recently, several new immune checkpoints have …
Emerging Targeted Therapies and Strategies to Overcome Resistance in Biliary Tract Cancers
T Demir, C Moloney, D Mahalingam - Critical Reviews in Oncology …, 2024 - Elsevier
In the last decade, targeted therapies have shown rapid advancement in biliary tract cancer
(BTC). Today, many targeted agents are available and under investigation for patients with …
(BTC). Today, many targeted agents are available and under investigation for patients with …
Combined hepatocellular-cholangiocarcinoma: from genesis to molecular pathways and therapeutic strategies
Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) are the most
common primary liver cancers. Little is known about the combined hepatocellular …
common primary liver cancers. Little is known about the combined hepatocellular …
m6A modification of AC026356.1 facilitates hepatocellular carcinoma progression by regulating the IGF2BP1-IL11 axis
H Wei, J Yang, R Lu, Y Huang, Z Huang, L Huang… - Scientific Reports, 2023 - nature.com
Abstract N6-methyladenosine (m6A) is the most common RNA modification in eukaryotic
RNAs. Although the important roles of m6A in RNA fate have been revealed, the potential …
RNAs. Although the important roles of m6A in RNA fate have been revealed, the potential …
[HTML][HTML] Suppression of alpha-tubulin acetylation potentiates therapeutic efficacy of Eribulin in liver cancer
Y Zhong, C Wang, Y Wang, Y Wu, H Wang… - American Journal of …, 2023 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is a prevalent cancer with limited effective treatments.
Eribulin mesylate is a novel chemotherapy drug that inhibits microtubule elongation and …
Eribulin mesylate is a novel chemotherapy drug that inhibits microtubule elongation and …
Comparison of drug-eluting bead with conventional transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: A …
TY Zhou, GF Tao, GH Zhou, YL Zhang… - … Journal of Surgery, 2024 - journals.lww.com
Background: Drug-eluting bead transarterial chemoembolization (DEB-TACE) has shown
efficacy for treating hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) …
efficacy for treating hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) …
[HTML][HTML] An herbal formula Shenlian decoction upregulates M1/M2 macrophage proportion in hepatocellular carcinoma by suppressing complement cascade
W Li, L You, J Lin, J Zhang, Z Zhou, T Wang… - Biomedicine & …, 2024 - Elsevier
The immunosuppressive microenvironment is a vital factor for the hepatocellular carcinoma
(HCC) progression. However, effective treatment is lacking at current. Shenlian decoction …
(HCC) progression. However, effective treatment is lacking at current. Shenlian decoction …
Self-delivery photothermal-boosted-nanobike multi-overcoming immune escape by photothermal/chemical/immune synergistic therapy against HCC
H Yang, W Mu, S Yuan, H Yang, L Chang… - Journal of …, 2024 - Springer
Immune checkpoint inhibitors (ICIs) combined with antiangiogenic therapy have shown
encouraging clinical benefits for the treatment of unresectable or metastatic hepatocellular …
encouraging clinical benefits for the treatment of unresectable or metastatic hepatocellular …
Programmed Death Ligand 1 Expression in Circulating Tumor Cells as a Predictor and Monitor of Response to Atezolizumab plus Bevacizumab Treatment in Patients …
T Nosaka, Y Murata, Y Akazawa, T Tanaka… - Cancers, 2024 - mdpi.com
Simple Summary Hepatocellular carcinoma (HCC) represents a significant health challenge,
demanding innovative approaches for effective treatment. Despite advances in immune …
demanding innovative approaches for effective treatment. Despite advances in immune …